$AQST
Aquestive Therapeutics, Inc. Stock $aqst

$aqst Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000162828021021207 Filed on November 02, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$11.08M	$13.29M	$7.149M
YoY Change	54.96%	60.86%	-56.46%
Cost Of Revenue	$3.366M	$4.400M	$2.788M
YoY Change	20.73%	47.75%	-58.95%
Gross Profit	$7.712M	$8.887M	$4.361M
YoY Change	76.84%	68.25%	-54.7%
Gross Profit Margin	69.62%	66.88%	61.0%
Selling, General & Admin	$14.98M	$12.13M	$15.58M
YoY Change	-3.84%	2.76%	-5.4%
% of Gross Profit	194.26%	136.48%	357.26%
Research & Development	$4.400M	$4.726M	$4.430M
YoY Change	-0.68%	-34.9%	44.77%
% of Gross Profit	57.05%	53.18%	101.58%
Depreciation & Amortization	$731.0K	$724.0K	$1.100M
YoY Change	-33.55%	1.4%	42.86%
% of Gross Profit	9.48%	8.15%	25.22%
Operating Expenses	$19.38M	$16.86M	$20.01M
YoY Change	-3.14%	-11.58%	-23.98%
Operating Profit	-$11.67M	-$7.968M	-$15.65M
YoY Change	-25.43%	-42.18%	-6.27%
Interest Expense	-$3.454M	$2.787M	-$4.720M
YoY Change	-26.82%	0.32%	72.89%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$28.95M	-$14.56M	-$20.37M
YoY Change	42.1%	-12.06%	61.16%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$28.95M	-$14.56M	-$20.37M
YoY Change	42.11%	-12.06%	61.19%
Net Earnings / Revenue	-261.28%	-109.54%	-284.91%
Basic Earnings Per Share		-$0.37
Diluted Earnings Per Share	-$716.2K	-$0.37	-$602.1K
COMMON SHARES
Basic Shares Outstanding	40.16M shares	39.22M shares	33.62M
Diluted Shares Outstanding		39.22M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.02M	$31.16M	$31.81M
YoY Change	-11.9%	82.67%	-35.52%
Cash & Equivalents	$28.02M	$31.16M	$31.81M
Short-Term Investments
Other Short-Term Assets	$3.077M	$2.540M	$3.400M
YoY Change	-9.5%	-25.07%	13.33%
Inventory	$4.038M	$2.863M	$2.461M
Prepaid Expenses
Receivables	$12.12M	$13.64M	$6.960M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$47.26M	$50.21M	$44.63M
YoY Change	5.9%	58.47%	-34.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.055M	$5.197M	$6.873M
YoY Change	-26.45%	-32.75%	-29.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.903M	$6.905M	$7.836M
YoY Change	-11.91%	2305.92%	2639.86%
Total Long-Term Assets	$14.73M	$15.08M	$18.26M
YoY Change	-19.31%	-19.51%	79.63%
TOTAL ASSETS
Total Short-Term Assets	$47.26M	$50.21M	$44.63M
Total Long-Term Assets	$14.73M	$15.08M	$18.26M
Total Assets	$61.99M	$65.29M	$62.88M
YoY Change	-1.42%	29.49%	-19.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.314M	$6.215M	$7.089M
YoY Change	17.28%	-32.22%	-42.24%
Accrued Expenses	$8.736M	$7.624M	$8.569M
YoY Change	1.95%	18.2%	56.51%
Deferred Revenue	$765.0K	$767.0K	$693.0K
YoY Change	10.39%	6.23%	-14.02%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.025M	$7.725M	$2.580M
YoY Change	-21.51%	341.43%
Total Short-Term Liabilities	$21.96M	$25.04M	$21.10M
YoY Change	4.08%	36.28%	13.74%
LONG-TERM LIABILITIES
Long-Term Debt	$51.55M	$32.67M	$34.33M
YoY Change	50.16%	-45.86%	-43.11%
Other Long-Term Liabilities	$2.485M	$1.810M	$1.945M
YoY Change	27.76%	-77.98%	43.01%
Total Long-Term Liabilities	$2.485M	$1.810M	$1.945M
YoY Change	27.76%	-97.36%	43.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.96M	$25.04M	$21.10M
Total Long-Term Liabilities	$2.485M	$1.810M	$1.945M
Total Liabilities	$144.1M	$125.6M	$111.4M
YoY Change	29.4%	44.51%	31.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$256.8M	-$227.9M	-$186.3M
YoY Change	37.87%	37.35%	42.75%
Common Stock	$41.00K	$40.00K	$35.00K
YoY Change	17.14%	17.65%	2.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$82.13M	-$60.35M	-$48.50M
YoY Change
Total Liabilities & Shareholders Equity	$61.99M	$65.29M	$62.88M
YoY Change	-1.42%	29.49%	-19.87%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$28.95M	-$14.56M	-$20.37M
YoY Change	42.11%	-12.06%	61.19%
Depreciation, Depletion And Amortization	$731.0K	$724.0K	$1.100M
YoY Change	-33.55%	1.4%	42.86%
Cash From Operating Activities	-$8.061M	-$9.065M	-$13.51M
YoY Change	-40.33%	8.95%	27.81%
INVESTING ACTIVITIES
Capital Expenditures	-$533.0K	-$83.00K	-$240.0K
YoY Change	122.08%	107.5%	200.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$533.0K	-$83.00K	-$240.0K
YoY Change	122.08%	107.5%	200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.454M	6.078M	28.49M
YoY Change	-80.86%		-27.08%
NET CHANGE
Cash From Operating Activities	-8.061M	-9.065M	-13.51M
Cash From Investing Activities	-533.0K	-83.00K	-240.0K
Cash From Financing Activities	5.454M	6.078M	28.49M
Net Change In Cash	-3.140M	-3.070M	14.74M
YoY Change	-121.3%	-63.28%	-48.14%
FREE CASH FLOW
Cash From Operating Activities	-$8.061M	-$9.065M	-$13.51M
Capital Expenditures	-$533.0K	-$83.00K	-$240.0K
Free Cash Flow	-$7.528M	-$8.982M	-$13.27M
YoY Change	-43.27%	8.48%	26.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	Aquestive Therapeutics, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001398733
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38599
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Address Address Line1 EntityAddressAddressLine1	30 Technology Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Warren
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07059
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3827296
	dei	City Area Code CityAreaCode	908
	dei	Local Phone Number LocalPhoneNumber	941-1900
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	AQST
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40164028	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31164000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31807000	USD
CY2021Q3	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	13643000	USD
CY2020Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	6955000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	2863000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	2461000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2540000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3402000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	50210000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	44625000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5197000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6873000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2917000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3448000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	64000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	102000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6905000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7836000	USD
CY2021Q3	us-gaap	Assets Assets	65293000	USD
CY2020Q4	us-gaap	Assets Assets	62884000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6215000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7089000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7624000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8569000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	860000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	728000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	767000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	693000	USD
CY2021Q3	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1848000	USD
CY2020Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1450000	USD
CY2021Q3	us-gaap	Loans Payable Current LoansPayableCurrent	7725000	USD
CY2020Q4	us-gaap	Loans Payable Current LoansPayableCurrent	2575000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	25039000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21104000	USD
CY2021Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	32673000	USD
CY2020Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	34329000	USD
CY2021Q3	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	56615000	USD
CY2020Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	47524000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2185000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2846000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7316000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3633000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1810000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1945000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	125638000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	111381000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40083245	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40083245	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34569254	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34569254	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	40000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	35000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	167466000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	137725000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-227851000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186257000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-60345000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-48497000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65293000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	62884000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13287000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8260000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39754000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38700000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4400000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2978000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11623000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10176000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4726000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7260000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12647000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15461000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12129000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11803000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38494000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40310000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	21255000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	22041000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	62764000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	65947000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7968000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13781000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23010000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27247000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	2787000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	2778000	USD
	us-gaap	Interest Expense InterestExpense	8305000	USD
	us-gaap	Interest Expense InterestExpense	8296000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	3767000	USD
CY2020Q3	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	0	USD
	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	10567000	USD
	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	0	USD
CY2021Q3	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	-33000	USD
CY2020Q3	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	8000	USD
	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	288000	USD
	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	128000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14555000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16551000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-41594000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35415000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14555000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-16551000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-41594000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35415000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14555000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16551000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41594000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35415000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39224863	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39224863	shares
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1710000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33619379	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33619379	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37297892	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37297892	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33592846	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33592846	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-48497000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10197000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-306000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1507000	USD
CY2021Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	27000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-14672000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-51798000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9241000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-627000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	76000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-53769000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6222000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-4000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12367000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-135000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1900000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-9000	USD
CY2021Q3	us-gaap	Stockholders Equity Other StockholdersEquityOther	-1000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14555000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-60345000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-6122000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1860000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-37000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-16530000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-20829000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	73000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1420000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-16551000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1754000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-52000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-2334000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-21388000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-36519000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-41594000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35415000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2233000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2337000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5128000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5052000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3604000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1758000	USD
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	10457000	USD
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	281000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-380000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	248000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-34000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	6726000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-5082000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	402000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	383000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1793000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7101000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-874000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3189000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2046000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	616000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3757000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-738000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24918000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31947000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	380000	USD
	aqst	Number Of Products Approved By Food And Drug Administration NumberOfProductsApprovedByFoodAndDrugAdministration	5	product
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	76000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-281000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	24592000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	62000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	13000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	96000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24655000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-34000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-643000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-32262000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31807000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49326000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31164000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17064000	USD
	us-gaap	Interest Paid Net InterestPaidNet	4828000	USD
	us-gaap	Interest Paid Net InterestPaidNet	6562000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31164000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-227851000	USD
CY2021Q3	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2637000	USD
CY2020Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3081000	USD
CY2021Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8083000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4326000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8260000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13287000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39754000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38700000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13287000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8260000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39754000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38700000	USD
CY2021Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	11500000	USD
CY2020Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	4330000	USD
CY2021Q3	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	2637000	USD
CY2020Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3081000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2021Q3	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	454000	USD
CY2020Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	416000	USD
CY2021Q3	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	13643000	USD
CY2020Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	6955000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	124000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	198000	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	282000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2020Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	2138000	USD
	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	6769000	USD
	aqst	Accounts Receivable Allowances Credits And Payments AccountsReceivableAllowancesCreditsAndPayments	5920000	USD
CY2021Q3	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	2987000	USD
	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	6769000	USD
CY2021Q3	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	454000	USD
CY2021Q3	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2533000	USD
CY2020Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	416000	USD
	us-gaap	Depreciation Depreciation	2127000	USD
CY2020Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	1722000	USD
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	938000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	789000	USD
CY2021Q3	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	1195000	USD
CY2020Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	1128000	USD
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	730000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	544000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	2863000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	2461000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5197000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44388000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47751000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39191000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	40878000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6873000	USD
CY2021Q3	us-gaap	Depreciation Depreciation	724000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	714000	USD
	us-gaap	Depreciation Depreciation	2195000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	322000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1294000	USD
CY2021Q3	aqst	Number Of Operating Leases NumberOfOperatingLeases	3	lease
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	431000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	1294000	USD
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	117000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	352000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	377000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	819000	USD
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	60000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	166000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	944000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	565000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	565000	USD
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	424000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4114000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1069000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3045000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2867000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2867000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2803000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2765000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	64000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	102000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	50000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	50000	USD
CY2021Q3	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	6000000	USD
CY2020Q4	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	7000000	USD
CY2021Q3	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	905000	USD
CY2020Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	836000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6905000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7836000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4596000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6330000	USD
CY2021Q3	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2533000	USD
CY2020Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	1722000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	495000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	517000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7624000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8569000	USD
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2019Q3	aqst	Net Proceeds From Issuance Of Initial Notes Warrants And First Offer Rights NetProceedsFromIssuanceOfInitialNotesWarrantsAndFirstOfferRights	66082000	USD
	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	USD
CY2020Q4	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	USD
CY2021Q3	us-gaap	Loans Payable Current LoansPayableCurrent	7725000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	2575000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	7725000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	12875000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	18025000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	10300000	USD
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	51500000	USD
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2909000	USD
CY2020Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	48974000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	110000	USD
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	10457000	USD
CY2021Q3	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	1848000	USD
CY2021Q3	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	58464000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14555000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-16551000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-41594000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35415000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39224863	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33619379	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37297892	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33592846	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1900000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1765000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5128000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3625000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1900000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1765000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5128000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3625000	USD
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	19270	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	14961	shares
	aqst	Stock Issued During Period Value Employee Stock Purchase Plans Discount StockIssuedDuringPeriodValueEmployeeStockPurchasePlansDiscount	11000	USD
	aqst	Stock Issued During Period Value Employee Stock Purchase Plans Discount StockIssuedDuringPeriodValueEmployeeStockPurchasePlansDiscount	11000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14555000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-16551000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-41594000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35415000	USD
CY2016Q3	aqst	Number Of States In The Antitrust Litigation NumberOfStatesInTheAntitrustLitigation	41	state

Files In Submission

Name	View Source	Status
0001628280-21-021207-index-headers.html	Edgar Link	pending
0001628280-21-021207-index.html	Edgar Link	pending
0001628280-21-021207.txt	Edgar Link	pending
0001628280-21-021207-xbrl.zip	Edgar Link	pending
aqst-09302021ex311.htm	Edgar Link	pending
aqst-09302021ex312.htm	Edgar Link	pending
aqst-09302021ex321.htm	Edgar Link	pending
aqst-09302021ex322.htm	Edgar Link	pending
aqst-20210930.htm	Edgar Link	pending
aqst-20210930.xsd	Edgar Link	pending
aqst-20210930_cal.xml	Edgar Link	unprocessable
aqst-20210930_def.xml	Edgar Link	unprocessable
aqst-20210930_htm.xml	Edgar Link	completed
aqst-20210930_lab.xml	Edgar Link	unprocessable
aqst-20210930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AQST
Aquestive Therapeutics, Inc. Stock $aqst

2021 Q4 Form 10-Q Financial Statement

#000162828021021207 Filed on November 02, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST Aquestive Therapeutics, Inc. Stock $aqst

2021 Q4 Form 10-Q Financial Statement

#000162828021021207 Filed on November 02, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST
Aquestive Therapeutics, Inc. Stock $aqst